Management

Born: 1971

Other current assignments: –

Experience: Jenny Sundqvist has extensive experience of research organizations and marketing of approved medicines. She has previously, among other things, been Chief Commercial Officer at Isofol Medical, Head of Portfolio Management for AstraZeneca’s global oncology portfolio and Global Brand Manager for AstraZeneca’s asthma product Symbicort. She has a BSc in International Trade & Finance from Louisiana State University and an MBA from McCombs School of Business.

Shareholding in InDex: Direct holding of 121 951 shares, 1 930 700 employee stock option (LTIP 2022) and 1 930 700 employee stock option (LTIP 2023).

Born: 1965.

Other current assignments: Giléus is a member of the board and CEO of Giléus Consulting AB and Giléus Invest AB. Giléus is also partner of Professionell ägarstyrning i Sverige AB.

Experience: Giléus is also engaged as an independent financial advisor with M&A, external financial reporting and other stock market issues. During the last 25 years Giléus has worked with Swedish and international strategic and financial clients in acquisitions and divestments. Giléus was until May 2015 partner at Deloitte AB with a focus on M&A and stock market issues. Giléus has studied business administration at Stockholm University.

Shareholding in InDex: Direct holding of 240 000 shares and indirect holding of 150 000 shares. Direct holding of 133 333 warrants (LTIP 2020) and 772 300 employee stock options (LTIP 2021), 772 300 employee stock options (LTIP 2022) and 772 300 employee stock options (LTIP 2023).

Born: 1964

Other current assignments: –

Experience: Eva Arlander has extensive experience from the pharmaceutical industry and has held senior positions at for example Astra Zeneca, Medivir and Affibody with a main focus on clinical development. She has also been department head at the Medical Products Agency. She is a pharmacist and holds a PhD in clinical pharmacology from the Karolinska Institutet.

Shareholding in InDex: Direct holding of 772 300 employee stock option (LTIP 2022) and 772 300 employee stock option (LTIP 2023).

Born: 1979

Other current assignments: –

Experience: Admyre has more than 15 years of experience from the pharmaceutical industry and has held several key positions within research and development, business development and investor relations. She holds a PhD in Immunology and a Master of Biomedicine from the Karolinska Institutet.

Shareholding in InDex: Direct holding of 9 036 shares and 58 333 warrants (LTIP 2020) and 338 000 employee stock options (LTIP 2021), 772 300 employee stock option (LTIP 2022) and 772 300 employee stock option (LTIP 2023).